While the majority of in vivo NOTCH3 studies in ovarian cancer testing the NOTCH3 effects have used activated NOTCH3 or its regulators, and γ-secretase inhibitors [52,63,64,65], Hu et al. have shown that silencing NOTCH3 with siRNA in a combination with paclitaxel reduced tumor proliferation and angiogenesis in SKOV3, A2780, and OVCAR5 cells [60]. The gene discussed is NOTCH3; the disease is neoplasm.